US Plasma Protease C1-Inhibitor Market Size study, by Drug Type (C1-inhibitors, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist) by Dosage Form (Lyphophlised, Injectables) Forecasts 2022-2032

US Plasma Protease C1-Inhibitor Market Size study, by Drug Type (C1-inhibitors, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist) by Dosage Form (Lyphophlised, Injectables) Forecasts 2022-2032

US Plasma Protease C1-Inhibitor Market is valued approximately USD 1229.25 million in 2023 and is anticipated to grow with a healthy growth rate of more than 17.57% over the forecast period 2024-2032. Plasma Protease C1-Inhibitor, also called C1-INH or C1 esterase inhibitor, is an essential blood protein that regulates the complement system and controls inflammation. As a natural inhibitor of proteases like C1s and C1r, which are integral to the classical pathway of the complement system, C1-INH prevents excessive activation of the complement cascade. This inhibition helps reduce the production of inflammatory mediators, thereby maintaining immune homeostasis and protecting tissues from damage. The rising trend towards the development of innovative delivery methods and formulations for Plasma Protease C1-Inhibitor products is a key trend that the supporting the growth of US Plasma Protease C1-Inhibitor Market during the estimate period of 2024-2032. This includes innovations in extended-release formulations, alternate dose regimens, and subcutaneous delivery to enhance patient comfort, adherence, and treatment outcomes.

The growing prevalence of Hereditary Angioedema (HAE) is a major factor that is acting as a catalyzing factor for the growth of the US Plasma Protease C1-Inhibitor Market. Effective therapies such as plasma protease C1 inhibitors are in higher demand. With more people being diagnosed with HAE, treatment options have advanced and patient access has increased due to increased awareness, increased diagnostic rates, and regulatory backing for novel medicines. Also, pharmaceutical companies in the region are actively involved in researching and developing new and improved C1-inhibitor therapies. These companies are working to meet the increasing demands of HAE patients in the US, and this is driving market expansion due to higher demand and an enlarged patient population. This includes exploring alternative delivery methods, extended-release formulations, and even gene therapies for HAE. The region benefits from a robust healthcare infrastructure, frequent product approvals, and major market players offering effective treatments for HAE patients. Favorable regulatory policies and approvals for Plasma Protease C1-Inhibitor products are facilitating their accessibility and adoption in United States, contributing to market expansion over the forecast period of 2024-2032. However, high price of esoteric testing procedures and stringent regulatory requirements is expected stifle market growth between 2022 and 2032.


Major market player included in this report are:
Ionis Pharmaceuticals, Inc.
BioCryst Pharmaceuticals
KalVista Pharmaceuticals, Inc.
Company 4
Company 5
Company 6
Company 7
Company 8
Company 9
Company 10



The detailed segments and sub-segment of the market are explained below:

By Drug Type
C1-inhibitors
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist

By Dosage Form
Lyphophlised
Injectables


Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and Country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions